On October 6, WUXI BIO rose 3.16% in regular trading, trading at HK$57.15/share with turnover of HK$135.6 million.

The pharmaceutical sector saw active trading as sector-wide gains gained momentum. Market optimism stems from strong mid-term earnings where revenue reached RMB11.787 billion and operating cash flow surged 137.2% year-over-year. Recent policy tailwinds including the Fifteen-Five Pharma Industry Plan support innovative drug platforms while upcoming global conferences like ESMO expect significant Chinese trial data disclosures.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)